In breast cancer, the combination of CDK4/6i with endocrine therapy became standard procedure and is certainly essential to restrict adaptive events, via reduction of Cyclin D1 levels and Cyclin E1 activity (102). This evidence concerns the gene CCND1 and breast carcinoma.